Spyre Therapeutics
Mark J. Rose is an accomplished expert in drug metabolism and pharmacokinetics with extensive experience in the biopharmaceutical industry. Currently serving as Vice President of DMPK and Nonclinical Safety at Spyre Therapeutics, Mark focuses on advancing next-generation therapeutics for inflammatory bowel disease. Previous roles include Vice President of DMPK at DTx Pharma, Executive Director and Head of DMPK at Gossamer Bio, and Director of Drug Metabolism and Pharmacokinetics at CHDI Management. Mark's earlier positions include Scientific Director at Amgen and Research Fellow at Merck & Co., where integral contributions were made to early-stage clinical trials and drug discovery. Mark holds a Ph.D. in Pharmaceutical Chemistry from The University of Kansas and a BS in Chemistry from Penn State University.
Spyre Therapeutics
Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.